NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=108477 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elanco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Elanco between November 7, 2023 and June 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2024 (GLOBE NEW ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Elanco investors who were adversely affected by alleged securities fraud between November 7, 2023 and June 26, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/elanco-animal-healt ...

文章核心观点 - 公司正在开发两款新药物Zenrelia和Credelio Quattro,预计在2024年获得FDA批准并上市 [1][2] - 但公司在2024年6月27日发布公告称,Zenrelia的美国标签将包含安全性方面的警示,预计会影响产品的市场接受度和销量 [2] - 同时公司也推迟了Zenrelia和Credelio Quattro的FDA批准和上市时间表 [2] - 这些负面消息导致公司股价在2024年6月27日下跌20.53% [2] 根据相关目录分别进行总结 公司概况 - 公司是一家从事宠物和农场动物药品研发、生产和销售的动物健康公司 [1] 新药研发进展 - 公司正在开发一种名为Zenrelia的每日一次口服JAK抑制剂,用于犬皮肤病治疗 [1] - 公司还在开发一种名为Credelio Quattro的广谱驱虫产品,用于犬 [1] - 公司原计划在2024年第三季度获得Zenrelia的FDA批准,第四季度上市 [2] - 公司原计划在2024年第四季度获得Credelio Quattro的FDA批准 [2] 新药审批进展 - 公司表示Zenrelia的美国标签将包含安全性方面的警示,这可能会影响产品的市场接受度和销量 [2] - 公司推迟了Zenrelia和Credelio Quattro的FDA批准和上市时间表 [2]

NEW YORK, Oct. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/? id=107864&fro ...

文章核心观点 - 艾兰科动物健康公司(Elanco Animal Health Incorporated)被指在2023年11月7日至2024年6月26日期间做出虚假和误导性陈述,隐瞒了公司产品Zenrelia和Credelio Quattro的安全性和上市时间表问题 [1][2][3] - 2024年6月27日,公司宣布Zenrelia的美国标签将包含安全警告,预计将减缓产品的采用和治疗天数约25% [3] - Zenrelia预计将在2024年第三季度获得FDA批准,并在第四季度商业化推出,Credelio Quattro也可能在第四季度获得FDA批准 [3] 公司概况 - 艾兰科是一家总部位于印第安纳州格林菲尔德的动物健康公司,专门从事宠物和牲畜用药及疫苗的开发和制造 [2] 行业信息 - 艾兰科股价在2024年6月27日下跌20.53%,每股从18.97美元下跌至14.28美元 [3]

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2024. SO WHAT: If you purchased Elanco Animal Health Incorpor ...

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

文章核心观点 - 根据诉讼,公司在2023年11月7日至2024年6月26日期间做出了虚假和/或误导性陈述,并未披露以下信息[3] 1) 公司开发的一种用于犬科皮肤病的JAK抑制剂Zenrelia的安全性低于公司向投资者披露的程度 2) 公司不太可能按照自己之前发布的时间表在美国获得Zenrelia和Credelio Quattro(一种犬用广谱驱虫产品)的批准和上市 3) 因此公司的业务和/或财务前景被夸大了 4) 公司的公开声明在所有相关时期都存在重大虚假和误导性 根据相关目录分别进行总结 诉讼背景 - 罗森律师事务所代表2023年11月7日至2024年6月26日期间购买Elanco Animal Health公司(纽交所代码:ELAN)证券的投资者提起集体诉讼[1][2] - 如果您在上述期间购买了Elanco Animal Health公司的证券,您可能有资格获得赔偿,无需支付任何费用或成本[1] 诉讼要求 - 如果您希望成为此集体诉讼的首席原告,您必须在2024年12月6日之前向法院提出申请[1][2] - 首席原告是代表其他集体成员指导诉讼的代表方[2] 诉讼细节 - 根据诉讼,公司在上述期间做出了虚假和/或误导性陈述,并未披露以下信息[3] 1) Zenrelia的安全性低于公司向投资者披露的程度 2) 公司不太可能按照自己之前发布的时间表在美国获得Zenrelia和Credelio Quattro的批准和上市 3) 因此公司的业务和/或财务前景被夸大了 4) 公司的公开声明在所有相关时期都存在重大虚假和误导性 - 当真实情况被披露时,投资者遭受了损失[3]